NovaBay Pharmaceuticals (NBY) Posts Break Even Q3 Loss
Tweet
Share
E-mailGet Alerts NBY Hot Sheet
Price: $0.08 --0%
Revenue Growth %: -14.6%
Financial Fact:
General and administrative: 2.22M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: -14.6%
Financial Fact:
General and administrative: 2.22M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
NovaBay Pharmaceuticals (NYSE: NBY) reported Q3 EPS of $0.00, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $3.64 million versus the consensus estimate of $3.08 million.
For earnings history and earnings-related data on NovaBay Pharmaceuticals (NBY) click here.
For earnings history and earnings-related data on NovaBay Pharmaceuticals (NBY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- Intuitive Surgical (ISRG) PT Raised to $435 at Piper Sandler
- Super Micro Computer (SMCI) now down nearly 20%
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
